Randomized IDE study met all primary and secondary safety and efficacy endpoints and demonstrated superior debris capture and significantly higher technical success versus the leading embolic protection control device in TAVR SANTA CRUZ, Calif., March 30, 2026 /PRNewswire/ — Emboline,…
Coronary/Structural Heart
FAST III trial demonstrates non-inferiority of CAAS vFFR to invasive wire-based FFR
FAST III was initiated five years ago to evaluate whether revascularization guided by angiography–based FFR using CAAS vFFR (vessel Fractional Flow Reserve) delivers therapeutic outcomes comparable to those achieved with pressure wire–based FFR. Positive non-inferior result validates…
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C Achieved THOUSAND OAKS, Calif., March…
HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation alone Late breaking findings presented at ACC.26 and simultaneously published…
How Decentralized AI is Unlocking Value in Cardiac Diagnostics
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER,BC, March 27, 2026 /PRNewswire/ — USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while…
Cleerly to Debut Cleerly PREVIEW and Showcase New AI-QCT Research at ACC.26
DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiovascular imaging analysis, will be attending the 75th Annual Scientific Session & Expo of the American College of Cardiology (ACC.26). The conference will take place March 28–30, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. ACC.26 convenes clinicians, researchers, and innovators from around the world to advance the science and practice of heart care. Cleerly will mark the conference with the launch of
AISAP and Cardiology Consultants of Philadelphia (CCP) Launch Strategic Partnership to Combat Heart Failure and Valvular Disease Through Advanced AI Cardiac Platform
The partnership will provide America’s largest independent cardiovascular practice with access to AISAP’s AI-enabled cardiac diagnostic platform NEW YORK and PHILADELPHIA, March 25, 2026 /PRNewswire/ — AISAP, a pioneer in AI-powered medical diagnostics, and Cardiology Consultants of…
Philips launches IntraSight Plus to simplify coronary interventions and advance precision care
March 25, 2026
CorVista Health to Present New Data on Non-Invasive Point of Care Test for Ischemia with Non-Obstructive Coronary Arteries Using Machine Learning at ACC.26
BETHESDA, Md.–(BUSINESS WIRE)–CorVista Health today announced the upcoming poster presentation of new data on its non-invasive point of care test for ischemia with non-obstructive coronary arteries (INOCA) – a common condition, particularly in women, where patients experience cardiovascular symptoms despite having no flow-limiting blockages in their major epicardial arteries – using machine learning at the American College of Cardiology’s Annual Scientific Session (ACC.26), taking place March
Clarius Unveils T-Mode™ Heart: New AI-Powered Training Tool Empowers Primary Care Physicians to Perform Cardiac Ultrasound Exams
By simplifying complex cardiac anatomy through real-time AI labeling, T-Mode™ Heart removes the training barrier to ultrasound adoption for family physicians and medical students. VANCOUVER, BC, March 23, 2026 /PRNewswire/ — With cardiovascular disease remaining a leading cause of death…
